- Home
- CLYM vs EPIX Comparison
CLYM vs EPIX Comparison
Compare CLYM & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLYM
- EPIX
- Stock Information
- Founded
- CLYM 2018
- EPIX 2009
- Country
- CLYM United States
- EPIX Canada
- Employees
- CLYM N/A
- EPIX N/A
- Industry
- CLYM
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- CLYM
- EPIX Health Care
- Exchange
- CLYM NYSE
- EPIX Nasdaq
- Market Cap
- CLYM 83.8M
- EPIX 75.9M
- IPO Year
- CLYM 2021
- EPIX N/A
- Fundamental
- Price
- CLYM $1.37
- EPIX $1.72
- Analyst Decision
- CLYM Buy
- EPIX Hold
- Analyst Count
- CLYM 1
- EPIX 3
- Target Price
- CLYM $10.00
- EPIX $2.00
- AVG Volume (30 Days)
- CLYM 389.6K
- EPIX 53.1K
- Earning Date
- CLYM 08-13-2025
- EPIX 08-04-2025
- Dividend Yield
- CLYM N/A
- EPIX N/A
- EPS Growth
- CLYM N/A
- EPIX N/A
- EPS
- CLYM N/A
- EPIX N/A
- Revenue
- CLYM N/A
- EPIX N/A
- Revenue This Year
- CLYM N/A
- EPIX N/A
- Revenue Next Year
- CLYM N/A
- EPIX N/A
- P/E Ratio
- CLYM N/A
- EPIX N/A
- Revenue Growth
- CLYM N/A
- EPIX N/A
- 52 Week Low
- CLYM $1.05
- EPIX $1.40
- 52 Week High
- CLYM $9.21
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- CLYM N/A
- EPIX 51.31
- Support Level
- CLYM N/A
- EPIX $1.68
- Resistance Level
- CLYM N/A
- EPIX $1.75
- Average True Range (ATR)
- CLYM 0.00
- EPIX 0.04
- MACD
- CLYM 0.00
- EPIX 0.00
- Stochastic Oscillator
- CLYM 0.00
- EPIX 62.50
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.